Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist

Ilana Graetz; Courtney R Yarbrough; Xin Hu; David H Howard

doi:10.1001/jamaoncol.2020.0804

Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist

JAMA Oncol. 2020 Jul 1;6(7):1102-1103. doi: 10.1001/jamaoncol.2020.0804.

Authors

Ilana Graetz¹, Courtney R Yarbrough¹, Xin Hu¹, David H Howard¹

Affiliation

¹ Winship Cancer Center, School of Public Health, Department of Health Policy and Management, Rollins Emory University, Atlanta, Georgia.

Abstract

This cohort study examines the association between prescription drug monitoring program mandates with and without a cancer exemption and the percent of oncologists’ patients with any opioid prescription covered by Medicare Part D.

MeSH terms

Analgesics, Opioid / therapeutic use*
Cancer Pain / drug therapy*
Humans
Medicare / statistics & numerical data*
Oncologists / statistics & numerical data*
Practice Patterns, Physicians'*
Prescription Drug Monitoring Programs*
United States

Substances

Analgesics, Opioid